Axi-cel proves effective as first-line treatment for high-risk lymphoma
University of Texas MD Anderson Cancer CenterResults from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, achieved a high rate of complete response in patients with high-risk large B-cell lymphoma (LBCL). The study was published today in Nature Medicine, and results recently were presented at the 2021 American Society of Hematology (ASH) meeting.